GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Race Oncology Ltd (ASX:RAC) » Definitions » EV-to-FCF

Race Oncology (ASX:RAC) EV-to-FCF : -218.61 (As of Mar. 02, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Race Oncology EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Race Oncology's Enterprise Value is A$179.26 Mil. Race Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.82 Mil. Therefore, Race Oncology's EV-to-FCF for today is -218.61.

The historical rank and industry rank for Race Oncology's EV-to-FCF or its related term are showing as below:

ASX:RAC' s EV-to-FCF Range Over the Past 10 Years
Min: -231.15   Med: 0   Max: 0
Current: -218.61

ASX:RAC's EV-to-FCF is ranked worse than
100% of 416 companies
in the Biotechnology industry
Industry Median: 4.095 vs ASX:RAC: -218.61

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-02), Race Oncology's stock price is A$1.14. Race Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.046. Therefore, Race Oncology's PE Ratio (TTM) for today is At Loss.


Race Oncology EV-to-FCF Historical Data

The historical data trend for Race Oncology's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Race Oncology EV-to-FCF Chart

Race Oncology Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
EV-to-FCF
Get a 7-Day Free Trial -32.39 -110.23 -44.35 -16.73 -30.76

Race Oncology Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -16.73 - -30.76 -

Competitive Comparison of Race Oncology's EV-to-FCF

For the Biotechnology subindustry, Race Oncology's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Race Oncology's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Race Oncology's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Race Oncology's EV-to-FCF falls into.



Race Oncology EV-to-FCF Calculation

Race Oncology's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=179.261/-0.82
=-218.61

Race Oncology's current Enterprise Value is A$179.26 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Race Oncology's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Race Oncology  (ASX:RAC) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Race Oncology's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.14/-0.046
=At Loss

Race Oncology's share price for today is A$1.14.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Race Oncology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was A$-0.046.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Race Oncology EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Race Oncology's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Race Oncology Business Description

Traded in Other Exchanges
N/A
Address
1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Race Oncology Ltd is a clinical stage biopharmaceutical company with a mission to be at the heart of cancer care. Its asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a clinical history with demonstrated therapeutic benefits in both adult and pediatric patients, a well-characterized safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin. It has reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where Race can deliver cardioprotection and enhanced anticancer activity in solid tumors.

Race Oncology Headlines

No Headlines